- Report
- April 2025
- 175 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- March 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- March 2025
- 250 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- June 2022
- 215 Pages
United States
From €2457EUR$2,699USD£2,086GBP
Kinrix is a combination vaccine used to protect against diphtheria, tetanus, pertussis, and polio. It is approved for use in children aged 4-6 years old. The vaccine is administered in a single dose and is typically given at the same time as other routine childhood vaccines. Kinrix is a combination of two vaccines, Infanrix and Kinrix, which are both manufactured by GlaxoSmithKline.
Kinrix is a part of the larger vaccine market, which is a rapidly growing industry. Vaccines are used to prevent and treat a variety of infectious diseases, and are an important part of public health initiatives. Vaccines are typically administered to children and adults, and are often required for school and work.
The Kinrix market is comprised of a number of companies, including GlaxoSmithKline, Merck, Pfizer, Sanofi, and Novartis. These companies produce a variety of vaccines, including combination vaccines like Kinrix. Additionally, there are a number of smaller companies that produce vaccines for specific diseases, such as influenza and measles. Show Less Read more